H.C. Wainwright analyst Joseph Pantginis upgraded BerGenBio to Buy from Neutral with a NOK 30 price target. "Now is an opportune time to step off the sidelines with BerGenBio, with its clear focus and strategy in place for bemcentinib," Pantginis tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly